Skip to main content
  • SURTAVI: 5 Years On, TAVR Shows Similar Outcomes to SAVR in Intermediate-Risk Patients

    Five years after aortic valve replacement in patients with intermediate surgical mortality risk, transcatheter aortic valve replacement (TAVR) with a self-expanding bioprosthetic valve and surgical aortic valve replacement (SAVR) had a similar composite rate of all-cause mortality or stroke, according to new trial results.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details